PURPOSE: The purpose of this study was to analyze the mode of relapse patterns and survival of 209 patients with stage IVA and IVB nasopharyngeal carcinoma (NPC). PATIENTS AND MATERIALS: A total of 209 patients who underwent magnetic resonance imaging (MRI) and were subsequently histologically diagnosed with nondisseminated stage IV NPC received intensity-modulated radiotherapy (IMRT) as their primary treatment and were included in this retrospective study. RESULTS: Median follow-up time was 65 months (range, 3-108 months). The 5-year overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates for patients with stage IVA and stage IVB NPC were 72.7 vs. 60.0 % (p = 0.319), 62.9 vs. 51.3 % (p = 0.070), 82.9 vs. 93.1 % (p = 0.070), 82.9 vs. 82.9 % (p = 0.897), 76.4 vs. 58.5 % (p = 0.003), respectively. Age older than 44 years was found to be a statistically significant adverse independent prognostic factor for OS. Patients with advanced N status had worse OS, DFS, and DMFS rates. Patients with a primary gross tumor volume (GTV-P) ≥ 55.11 ml had worse OS, DFS, and LRRFS rates. CONCLUSION: The results of treating stage IVA NPC with IMRT were excellent. Distant metastasis remains the most difficult treatment challenge for patients with stage IVA and IVB NPC, and more effective systemic chemotherapy should be explored.
PURPOSE: The purpose of this study was to analyze the mode of relapse patterns and survival of 209 patients with stage IVA and IVB nasopharyngeal carcinoma (NPC). PATIENTS AND MATERIALS: A total of 209 patients who underwent magnetic resonance imaging (MRI) and were subsequently histologically diagnosed with nondisseminated stage IV NPC received intensity-modulated radiotherapy (IMRT) as their primary treatment and were included in this retrospective study. RESULTS: Median follow-up time was 65 months (range, 3-108 months). The 5-year overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), locoregional recurrence-free survival (LRRFS), and distant metastasis-free survival (DMFS) rates for patients with stage IVA and stage IVB NPC were 72.7 vs. 60.0 % (p = 0.319), 62.9 vs. 51.3 % (p = 0.070), 82.9 vs. 93.1 % (p = 0.070), 82.9 vs. 82.9 % (p = 0.897), 76.4 vs. 58.5 % (p = 0.003), respectively. Age older than 44 years was found to be a statistically significant adverse independent prognostic factor for OS. Patients with advanced N status had worse OS, DFS, and DMFS rates. Patients with a primary gross tumor volume (GTV-P) ≥ 55.11 ml had worse OS, DFS, and LRRFS rates. CONCLUSION: The results of treating stage IVA NPC with IMRT were excellent. Distant metastasis remains the most difficult treatment challenge for patients with stage IVA and IVB NPC, and more effective systemic chemotherapy should be explored.
Authors: Wai Tong Ng; Michael C H Lee; Wai Man Hung; Cheuk Wai Choi; Kin Chung Lee; Oscar S H Chan; Anne W M Lee Journal: Int J Radiat Oncol Biol Phys Date: 2010-05-06 Impact factor: 7.038
Authors: D M Heng; J Wee; K W Fong; L G Lian; V K Sethi; E T Chua; T L Yang; H S Khoo Tan; K S Lee; K M Lee; T Tan; E J Chua Journal: Cancer Date: 1999-11-15 Impact factor: 6.860
Authors: R L Hong; L L Ting; J Y Ko; M M Hsu; T S Sheen; P J Lou; C C Wang; N N Chung; L T Lui Journal: J Clin Oncol Date: 2001-12-01 Impact factor: 44.544
Authors: Anthony T C Chan; Mow-Ming Hsu; Boon C Goh; Edwin P Hui; Tsang-Wu Liu; Michael J Millward; Ruey-Long Hong; Jacqueline Whang-Peng; Brigette B Y Ma; Ka F To; Matthias Mueser; Nadia Amellal; Xiao Lin; Alex Y Chang Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: G Sanguineti; F B Geara; A S Garden; S L Tucker; K K Ang; W H Morrison; L J Peters Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-15 Impact factor: 7.038
Authors: Suzanne L Wolden; William C Chen; David G Pfister; Dennis H Kraus; Sean L Berry; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-02 Impact factor: 7.038
Authors: Nancy Y Lee; Qiang Zhang; David G Pfister; John Kim; Adam S Garden; James Mechalakos; Kenneth Hu; Quynh T Le; A Dimitrios Colevas; Bonnie S Glisson; Anthony Tc Chan; K Kian Ang Journal: Lancet Oncol Date: 2011-12-15 Impact factor: 41.316